Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in Recurrent EGFR-Amplified Glioblastoma
NCT01520870Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Feb 2012
- Primary completion
- Apr 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dacomitinib in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Started Feb 2012; status: completed.
02
Drugs
dacomitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01520870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01520870.